Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman
January 03 2018 - 7:00AM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta therapeutics
to treat serious and rare diseases, today announced the planned
retirement of Executive Vice President and Chief Medical Officer
Matthew L. Sherman, M.D. The retirement will be effective after the
topline data release from the ongoing MEDALIST and BELIEVE Phase 3
clinical trials with luspatercept, expected to occur in the middle
of this year. Luspatercept is the Company’s lead program that is
being developed across multiple Phase 3 and Phase 2 clinical trials
in collaboration with Celgene Corporation for the treatment of
chronic anemia in hematologic disorders.
Dr. Sherman joined Acceleron in 2006 as its first Chief Medical
Officer. Dr. Sherman has successfully led the clinical development
of multiple internally discovered programs, most notably the Phase
1 and Phase 2 clinical trials of luspatercept.
“I am sincerely grateful to Matt for his dedicated service to
Acceleron throughout the past twelve years and for his support
through my first year as CEO,” said Habib Dable, President and
Chief Executive Officer of Acceleron. “Matt has provided valuable
leadership and clinical development experience to Acceleron,
especially in the areas of hematology and oncology. I am delighted
that we will continue to benefit from Matt’s expertise in support
of the anticipated process for regulatory approval of
luspatercept."
"I am truly proud of our achievements at Acceleron over the last
twelve years, including building an outstanding clinical
development team, advancing multiple protein therapeutics into
Phase 2 development and working strategically alongside our
collaboration partner for the ongoing Phase 3 trials of
luspatercept. I am looking forward to continuing to work on the
luspatercept program. Acceleron is well-positioned for continued
success and I am excited about the future of the company in all
areas," said Dr. Sherman.
Dr. Sherman will remain on staff until the release of topline
data from the MEDALIST and BELIEVE trials, and then serve in an
advisory capacity for one year thereafter. The Company is now
initiating a search for the position of Chief Medical Officer.
About Acceleron
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical
company dedicated to the discovery, development, and
commercialization of therapeutics to treat serious and rare
diseases. The Company's leadership in the understanding of TGF-beta
biology and protein engineering generates innovative compounds that
engage the body's ability to regulate cellular growth and
repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary
program with a Phase 2 trial of sotatercept planned in pulmonary
arterial hypertension.
For more information, please visit www.acceleronpharma.com/.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements about the
Company's strategy, future plans and prospects, including
statements regarding the development of the Company's compounds,
the timeline for clinical development and regulatory approval of
the Company's compounds and the expected timing for reporting of
data from ongoing clinical trials. The words "anticipate,"
"believe," "could," "estimate," "expect," "goal", "intend," "may,"
"plan," "potential," "project," "should," "target," "will,"
"would," and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Actual results could differ materially from those included in
the forward-looking statements due to various risks and
uncertainties, including, but not limited to, that preclinical
testing of the Company's compounds and data from clinical trials
may not be predictive of the results or success of ongoing or later
clinical trials, that the development of the Company's compounds
will take longer and/or cost more than planned, that the Company or
its collaboration partner, Celgene, will be unable to successfully
complete the clinical development of the Company's compounds, that
the Company or Celgene may be delayed in initiating, enrolling or
completing any clinical trials, and that the Company's compounds
will not receive regulatory approval or become commercially
successful products. These and other risks and uncertainties are
identified under the heading "Risk Factors" included in the
Company's most recent Annual Report on Form 10-K, and other filings
that the Company has made and may make with the SEC in
the future.
The forward-looking statements contained in this press release
are based on management's current views, plans, estimates,
assumptions and projections with respect to future events, and the
Company does not undertake and specifically disclaims any
obligation to update any forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180103005258/en/
Acceleron Pharma Inc.Todd James, IRC, 617-649-9393Vice
President, Investor Relations and Corporate CommunicationsorCandice
Ellis, 617-649-9226Manager, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
646-513-3125
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Sep 2023 to Sep 2024